These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 32286643)

  • 1. Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial.
    Chen GL; Coates EE; Plummer SH; Carter CA; Berkowitz N; Conan-Cibotti M; Cox JH; Beck A; O'Callahan M; Andrews C; Gordon IJ; Larkin B; Lampley R; Kaltovich F; Gall J; Carlton K; Mendy J; Haney D; May J; Bray A; Bailer RT; Dowd KA; Brockett B; Gordon D; Koup RA; Schwartz R; Mascola JR; Graham BS; Pierson TC; Donastorg Y; Rosario N; Pape JW; Hoen B; Cabié A; Diaz C; Ledgerwood JE;
    JAMA; 2020 Apr; 323(14):1369-1377. PubMed ID: 32286643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial.
    Chang LJ; Dowd KA; Mendoza FH; Saunders JG; Sitar S; Plummer SH; Yamshchikov G; Sarwar UN; Hu Z; Enama ME; Bailer RT; Koup RA; Schwartz RM; Akahata W; Nabel GJ; Mascola JR; Pierson TC; Graham BS; Ledgerwood JE;
    Lancet; 2014 Dec; 384(9959):2046-52. PubMed ID: 25132507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.
    Reisinger EC; Tschismarov R; Beubler E; Wiedermann U; Firbas C; Loebermann M; Pfeiffer A; Muellner M; Tauber E; Ramsauer K
    Lancet; 2019 Dec; 392(10165):2718-2727. PubMed ID: 30409443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccination with a chikungunya virus-like particle vaccine exacerbates disease in aged mice.
    Arévalo MT; Huang Y; Jones CA; Ross TM
    PLoS Negl Trop Dis; 2019 Apr; 13(4):e0007316. PubMed ID: 31026260
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1, randomized, placebo-controlled, dose-ranging study to evaluate the safety and immunogenicity of an mRNA-based chikungunya virus vaccine in healthy adults.
    Shaw CA; August A; Bart S; Booth PJ; Knightly C; Brasel T; Weaver SC; Zhou H; Panther L
    Vaccine; 2023 Jun; 41(26):3898-3906. PubMed ID: 37210308
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel intramuscular bivalent norovirus virus-like particle vaccine candidate--reactogenicity, safety, and immunogenicity in a phase 1 trial in healthy adults.
    Treanor JJ; Atmar RL; Frey SE; Gormley R; Chen WH; Ferreira J; Goodwin R; Borkowski A; Clemens R; Mendelman PM
    J Infect Dis; 2014 Dec; 210(11):1763-71. PubMed ID: 24951828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: a randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial.
    Ramsauer K; Schwameis M; Firbas C; Müllner M; Putnak RJ; Thomas SJ; Desprès P; Tauber E; Jilma B; Tangy F
    Lancet Infect Dis; 2015 May; 15(5):519-27. PubMed ID: 25739878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials.
    Xia S; Duan K; Zhang Y; Zhao D; Zhang H; Xie Z; Li X; Peng C; Zhang Y; Zhang W; Yang Y; Chen W; Gao X; You W; Wang X; Wang Z; Shi Z; Wang Y; Yang X; Zhang L; Huang L; Wang Q; Lu J; Yang Y; Guo J; Zhou W; Wan X; Wu C; Wang W; Huang S; Du J; Meng Z; Pan A; Yuan Z; Shen S; Guo W; Yang X
    JAMA; 2020 Sep; 324(10):951-960. PubMed ID: 32789505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-Immunization With CHIKV VLP and DNA Vaccines Induces a Promising Humoral Response in Mice.
    Zhao Z; Deng Y; Niu P; Song J; Wang W; Du Y; Huang B; Wang W; Zhang L; Zhao P; Tan W
    Front Immunol; 2021; 12():655743. PubMed ID: 33868299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A single dose of ChAdOx1 Chik vaccine induces neutralizing antibodies against four chikungunya virus lineages in a phase 1 clinical trial.
    Folegatti PM; Harrison K; Preciado-Llanes L; Lopez FR; Bittaye M; Kim YC; Flaxman A; Bellamy D; Makinson R; Sheridan J; Azar SR; Campos RK; Tilley M; Tran N; Jenkin D; Poulton I; Lawrie A; Roberts R; Berrie E; Rossi SL; Hill A; Ewer KJ; Reyes-Sandoval A
    Nat Commun; 2021 Jul; 12(1):4636. PubMed ID: 34330906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-Inactivated and Virus-Like Particle Vaccine Strategies for Chikungunya Virus.
    DeZure AD; Berkowitz NM; Graham BS; Ledgerwood JE
    J Infect Dis; 2016 Dec; 214(suppl 5):S497-S499. PubMed ID: 27920180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chikungunya virus virus-like particle vaccine is well tolerated and immunogenic in chikungunya seropositive individuals.
    McCarty JM; Bedell L; Mendy J; Coates EE; Chen GL; Ledgerwood JE; Tredo SR; Warfield KL; Richardson JS
    Vaccine; 2023 Oct; 41(42):6146-6149. PubMed ID: 37690874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Virus-Like Particle Vaccine Elicits Broad Neutralizing Antibody Responses in Humans to All Chikungunya Virus Genotypes.
    Goo L; Dowd KA; Lin TY; Mascola JR; Graham BS; Ledgerwood JE; Pierson TC
    J Infect Dis; 2016 Nov; 214(10):1487-1491. PubMed ID: 27655868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Single-shot live-attenuated chikungunya vaccine in healthy adults: a phase 1, randomised controlled trial.
    Wressnigg N; Hochreiter R; Zoihsl O; Fritzer A; Bézay N; Klingler A; Lingnau K; Schneider M; Lundberg U; Meinke A; Larcher-Senn J; Čorbic-Ramljak I; Eder-Lingelbach S; Dubischar K; Bender W
    Lancet Infect Dis; 2020 Oct; 20(10):1193-1203. PubMed ID: 32497524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and immunogenicity of a trivalent virus-like particle vaccine against western, eastern, and Venezuelan equine encephalitis viruses: a phase 1, open-label, dose-escalation, randomised clinical trial.
    Coates EE; Edupuganti S; Chen GL; Happe M; Strom L; Widge A; Florez MB; Cox JH; Gordon I; Plummer S; Ola A; Yamshchikov G; Andrews C; Curate-Ingram S; Morgan P; Nagar S; Collins MH; Bray A; Nguyen T; Stein J; Case CL; Kaltovich F; Wycuff D; Liang CJ; Carlton K; Vazquez S; Mascola JR; Ledgerwood JE;
    Lancet Infect Dis; 2022 Aug; 22(8):1210-1220. PubMed ID: 35568049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study.
    Heppner DG; Kemp TL; Martin BK; Ramsey WJ; Nichols R; Dasen EJ; Link CJ; Das R; Xu ZJ; Sheldon EA; Nowak TA; Monath TP;
    Lancet Infect Dis; 2017 Aug; 17(8):854-866. PubMed ID: 28606591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blinded Phase 3 study to demonstrate lot-to-lot consistency and to confirm immunogenicity and safety of the live-attenuated chikungunya virus vaccine candidate VLA1553 in healthy adults†.
    McMahon R; Fuchs U; Schneider M; Hadl S; Hochreiter R; Bitzer A; Kosulin K; Koren M; Mader R; Zoihsl O; Wressnigg N; Dubischar K; Buerger V; Eder-Lingelbach S; Jaramillo JC
    J Travel Med; 2024 Mar; 31(2):. PubMed ID: 38091981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of PXVX0317, an aluminium hydroxide-adjuvanted chikungunya virus-like particle vaccine: a randomised, double-blind, parallel-group, phase 2 trial.
    Bennett SR; McCarty JM; Ramanathan R; Mendy J; Richardson JS; Smith J; Alexander J; Ledgerwood JE; de Lame PA; Royalty Tredo S; Warfield KL; Bedell L
    Lancet Infect Dis; 2022 Sep; 22(9):1343-1355. PubMed ID: 35709798
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial.
    Modjarrad K; Roberts CC; Mills KT; Castellano AR; Paolino K; Muthumani K; Reuschel EL; Robb ML; Racine T; Oh MD; Lamarre C; Zaidi FI; Boyer J; Kudchodkar SB; Jeong M; Darden JM; Park YK; Scott PT; Remigio C; Parikh AP; Wise MC; Patel A; Duperret EK; Kim KY; Choi H; White S; Bagarazzi M; May JM; Kane D; Lee H; Kobinger G; Michael NL; Weiner DB; Thomas SJ; Maslow JN
    Lancet Infect Dis; 2019 Sep; 19(9):1013-1022. PubMed ID: 31351922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.